Post-Hoc Analysis Shows Pharmacogenomic Testing Speeds Depression Treatment Response
The GeneSight test results led to faster initial remission and response in patients with major depressive disorder, with benefits persisting over six months.
The GeneSight test results led to faster initial remission and response in patients with major depressive disorder, with benefits persisting over six months.
A new study informed use of PARP inhibitors beyond BRCA1/2-deficient tumors and reevaluated biomarkers for PARP inhibition in prostate cancer.
A researcher is using nanodisks to provide a way to rapidly and efficiently identify and monitor small cancer cells.